相关实验视频
Updated: Jun 27, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.7K
关于低血糖效应和黄类药物的分子机制的研究进展:一篇评论
Mengyi Liu1,2, Chunlong Liu2, Puba Zhaxi3
1School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China.
Antioxidants (Basel, Switzerland)
|April 29, 2025
概括
在植物中发现的天然化合物黄酸,通过降低血糖来控制糖尿病,显示出显著的潜力. 这篇评论详细介绍了它们的机制和对葡萄糖代谢的多种影响,为未来的糖尿病治疗提供了洞察力.
科学领域:
- 代谢障碍和内分泌学
- 营养生物化学和植物化学
背景情况:
- 糖尿病是一种日益严重的全球健康问题,需要新的治疗策略.
- 天然植物化学物质,特别是黄类,具有已被证明的低血糖特性.
- 黄类药物为替代糖尿病管理提供了一个有希望的途径.
研究的目的:
- 综合审查各种黄类子类别的低血糖影响.
- 为了阐明分子标和信号通路参与了黄胺介导的葡萄糖调节.
- 探索黄素在调节肠道微生物群中的作用及其代谢影响.
主要方法:
- 系统性文献综述最近关于黄类低血糖特性的研究.
- 详细分析了与关键代谢酶 (如α-氨酶,α-葡萄糖酶) 的黄类相互作用的研究结果.
- 检查研究调查信号通路的研究,如IRS/PI3K/AKT和PERK/eIF2α/ATF4/CHOP.
主要成果:
- 黄类药物有效抑制碳水化合物代谢和葡萄糖生成.
- 黄类药物增强葡萄糖吸收,糖生成和胰岛素分泌.
- 黄类药物减轻胰岛素抵抗,氧化应激和炎症;有些具有协同作用.
结论:
- 黄类药物代表了糖尿病管理的多方面的治疗类.
- 它们的机制涉及直接的酶抑制,信号通路调节和肠道微生物群相互作用.
- 对特定的黄类的进一步研究可能会产生强效的天然抗糖尿病药物.
相关概念视频
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

